The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab
Study Details
Study Description
Brief Summary
The investigators hope that the present study will highlight new transcriptomic prognostic markers of response to Ustekinumab with the ultimate goal of individualizing treatment and making a more targeted selection of UC patients who will benefit from this biological agent.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Introduction: Optimizing treatment with biological agents is an ideal goal for patients with ulcerative colitis (UC). At present, there are insufficient prognostic markers of response to each biological agent, which makes it difficult to individualize treatment. Recent data suggest that mucosal inflammation patterns and serum cytokine profiles differ between patients who respond and those who do not. These studies mainly focused on anti-TNFα agents and Vedolizumab, while there are no corresponding data for Ustekinumab, which is a monoclonal antibody to interleukins 12 and 23 and has recently been approved for the treatment of patients with UC.
Aim of the study: To highlight prognostic markers of response (clinical and endoscopic) to Ustekinumab, in patients with UC, utilizing information from their transcriptome before starting treatment.
Methods: This is a prospective, single-center cohort study that will evaluate transcriptomic markers of response to Ustekinumab in patients with active UC. The diagnosis of the disease will be based on the established clinical, endoscopic and histological criteria. The patients' recruitment will begin in April 2022, while their consent will be required. The duration of follow-up of patients will be at least 6 months from the start of biological treatment. Patients will undergo endoscopy (sigmoidoscopy or total colonoscopy) with a biopsy of the orthosigmoid before the start of biological treatment and a repeat endoscopy 6 months later. The RNA profile of the patients will be recorded after isolation of the total RNA from colon biopsies. Then, using biostatistics, the transcriptomic profiles of patients who responded to Ustekinumab and those who did not respond to 6 months of treatment, will be compared.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Ulcerative colitis patients treated with ustekinumab Patients with Ulcerative Colitis treated with ustekinumab |
Drug: Ustekinumab
Patients with ulcerative colitis treated with ustekinumab
|
Outcome Measures
Primary Outcome Measures
- the rate of clinical remission [6 months]
Total Mayo score of 2 or lower and no subscore higher than 1
Secondary Outcome Measures
- Endoscopic response rate [6 months]
Reduction of the endoscopic Mayo subscore ≥1
- Clinical response rate [6 months]
Reduction in the Mayo score of at least 3 points and a decrease of at least 30% from the baseline score, with a decrease of at least 1 point on the rectal bleeding subscale or an Absolute rectal bleeding score of 0 or 1
- Endoscopic remission rate [6 months]
Endoscopic Mayo subscore 0
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Active UC in accordance with applicable diagnostic criteria [25] •
-
Aged 18 or above
Exclusion Criteria:
-
Prior surgical history for UC
-
Toxic megacolon
-
Infectious complications (Cl. Difficile, CMV infection)
-
Patients who received any approved biologic agent (e.g. Infliximab, adalimumab, vedolizumab, golimumab) within the previous 8 weeks or any investigational biologic or other agent in the last 35 days
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Evangelismos Hospital | Athens | Attiki | Greece | 10676 |
Sponsors and Collaborators
- Evangelismos Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 479/15-12-2022